RESUMO
In 1900, Ernst Overton found that the entry of anilin dyes through the cell membranes of living cells depended on the lipophilicity of the dyes. The brain is surrounded by barriers consisting of lipid layers that possess several inward and outward active transport systems. In the absence of meningeal inflammation, the cerebrospinal fluid (CSF) penetration of anti-infectives in humans estimated by the ratio of the area under the concentration-time curve (AUC) in CSF (AUC(CSF)) to that in serum (AUC(CSF)/AUC(S)) correlated positively with the lipid-water partition coefficient at pH 7.0 (log D) (Spearman's rank correlation coefficient r(S) = 0.40; P = 0.01) and negatively with the molecular mass (MM) (r(S) = -0.33; P = 0.04). The ratio of AUC(CSF) to the AUC of the fraction in serum that was not bound (AUC(CSF)/AUC(S,free)) strongly correlated with log D (r(S) = 0.67; P < 0.0001). In the presence of meningeal inflammation, AUC(CSF)/AUC(S) also correlated positively with log D (r(S) = 0.46; P = 0.002) and negatively with the MM (r(S) = -0.37; P = 0.01). The correlation of AUC(CSF)/AUC(S,free) with log D (r(S) = 0.66; P < 0.0001) was as strong as in the absence of meningeal inflammation. Despite these clear correlations, Overton's rule was able to explain only part of the differences in CSF penetration of the individual compounds. The site of CSF withdrawal (lumbar versus ventricular CSF), age of the patients, underlying diseases, active transport, and alterations in the pharmacokinetics by comedications also appeared to strongly influence the CSF penetration of the drugs studied.
Assuntos
Anti-Infecciosos/líquido cefalorraquidiano , Anti-Infecciosos/farmacocinética , Líquido Cefalorraquidiano/química , Anti-Infecciosos/sangue , Área Sob a Curva , Transporte Biológico Ativo , Encéfalo/metabolismo , Humanos , Meninges/metabolismoRESUMO
The entry of anti-infectives into the central nervous system (CNS) depends on the compartment studied, molecular size, electric charge, lipophilicity, plasma protein binding, affinity to active transport systems at the blood-brain/blood-cerebrospinal fluid (CSF) barrier, and host factors such as meningeal inflammation and CSF flow. Since concentrations in microdialysates and abscesses are not frequently available for humans, this review focuses on drug CSF concentrations. The ideal compound to treat CNS infections is of small molecular size, is moderately lipophilic, has a low level of plasma protein binding, has a volume of distribution of around 1 liter/kg, and is not a strong ligand of an efflux pump at the blood-brain or blood-CSF barrier. When several equally active compounds are available, a drug which comes close to these physicochemical and pharmacokinetic properties should be preferred. Several anti-infectives (e.g., isoniazid, pyrazinamide, linezolid, metronidazole, fluconazole, and some fluoroquinolones) reach a CSF-to-serum ratio of the areas under the curves close to 1.0 and, therefore, are extremely valuable for the treatment of CNS infections. In many cases, however, pharmacokinetics have to be balanced against in vitro activity. Direct injection of drugs, which do not readily penetrate into the CNS, into the ventricular or lumbar CSF is indicated when other effective therapeutic options are unavailable.
Assuntos
Anti-Infecciosos/uso terapêutico , Barreira Hematoencefálica/metabolismo , Infecções do Sistema Nervoso Central/líquido cefalorraquidiano , Infecções do Sistema Nervoso Central/tratamento farmacológico , Sistema Nervoso Central/efeitos dos fármacos , Anti-Infecciosos/líquido cefalorraquidiano , Anti-Infecciosos/farmacocinética , Transporte Biológico Ativo , Barreira Hematoencefálica/microbiologia , Sistema Nervoso Central/fisiopatologia , Infecções do Sistema Nervoso Central/metabolismo , HumanosRESUMO
OBJECTIVE: Evaluation of an analytic method for determining linezolid concentrations in biological fluids including plasma, vitreous humour and cerebrospinal fluid using high-efficiency liquid chromatography and subsequent ultraviolet detection. METHOD: The method was validated by studying the following parameters: accuracy, precision, sensitivity, linearity and recovery. The drug was extracted from the biological matrix by means of a protein precipitation with perchloric acid. Chromatographic separation was performed by eluting linezolid with a mobile phase consisting of 80% K2HPO4 buffer solution (15 mM; pH=5) and 20% acetonitrile, and a stationary phase, NOVAPAK C18 150x3.9 mm with precolumn. The wavelength reading was 254 nm and the working flow rate was 1 ml/min. RESULTS: We obtained values with accuracies between 94.4 and 106.1%, and precisions between 0.88-6% and 3.7-5.6% for intra-and inter-day variability, respectively. Recovery obtained after analysing the plasma samples was at 93%. The method showed itself to be linear for the concentration levels under study. DISCUSSION: The method's behaviour can be described as linear, precise and accurate. Furthermore, the method is fast, sensitive, and inexpensive. It is useful for determining linezolid concentrations in multiple biological matrices. It can also be used as a basis for further clinical pharmacokinetic studies.
Assuntos
Acetamidas/análise , Anti-Infecciosos/análise , Cromatografia Líquida , Oxazolidinonas/análise , Acetamidas/sangue , Acetamidas/líquido cefalorraquidiano , Anti-Infecciosos/sangue , Anti-Infecciosos/líquido cefalorraquidiano , Humanos , Linezolida , Oxazolidinonas/sangue , Oxazolidinonas/líquido cefalorraquidiano , Corpo Vítreo/químicaAssuntos
Enterococcus faecium/isolamento & purificação , Meningites Bacterianas/microbiologia , Resistência a Vancomicina , Acetamidas/efeitos adversos , Acetamidas/líquido cefalorraquidiano , Acetamidas/uso terapêutico , Anti-Infecciosos/efeitos adversos , Anti-Infecciosos/líquido cefalorraquidiano , Anti-Infecciosos/uso terapêutico , Enterococcus faecium/efeitos dos fármacos , Enterococcus faecium/genética , Feminino , Humanos , Recém-Nascido , Linezolida , Meningites Bacterianas/tratamento farmacológico , Testes de Sensibilidade Microbiana , Oxazolidinonas/efeitos adversos , Oxazolidinonas/líquido cefalorraquidiano , Oxazolidinonas/uso terapêutico , Nascimento Prematuro , Resultado do Tratamento , Derivação Ventriculoperitoneal/efeitos adversosRESUMO
To compare the efficacy of meropenem, ceftazidime, tobramycin and ceftazidime+tobramycin in a guinea-pig model of P. aeruginosa meningitis. After anesthesia, the atlanto-occipital membrane was punctured with a butterfly needle and 100 microl of a solution containing 10(6)CFU/ml of P. aeruginosa were injected directly into the cisterna magna. Four h later, therapy was initiated with saline or antibiotics given im for 48 h in doses that obtained CSF levels as in human meningitis: ceftazidime 200 mg/kg/8h, meropenem 200 mg/kg/8h, tobramycin 30 mg/kg/24h. Tobramycin was also given intracisternally. Animals were sacrificed at different time points. CSF and blood samples were collected and a meningeal swab was performed. Four hours after inoculation, bacterial concentration in CSF was 4 to 5log10CFU and mean WBC was 16,000/-l. All control animals died in 24h with a 12% increase in cerebral edema. All blood-cultures were negative. Ceftazidime, ceftazidime+tobramycin and meropenem reduced the CSF bacterial concentration at 8h by 2.5log10. At 48 h all CSF cultures were sterile but meningeal swab cultures remained positive in 30%. Our results suggest that meropenem may be at least as effective as ceftazidime and that the addition of tobramycin to ceftazidime may improve its efficacy.
Assuntos
Anti-Infecciosos/farmacologia , Meningite/tratamento farmacológico , Pseudomonas aeruginosa/crescimento & desenvolvimento , Animais , Anti-Infecciosos/líquido cefalorraquidiano , Anti-Infecciosos/farmacocinética , Modelos Animais de Doenças , Quimioterapia Combinada , Feminino , Cobaias , Humanos , Meningite/líquido cefalorraquidiano , Meningite/metabolismo , Meningite/microbiologiaRESUMO
This study used pharmacokinetic-pharmacodynamic (PK-PD) modelling and MICs of 15 antimicrobial agents, derived from testing a large international culture collection, to assist in the development of interpretative criteria, i.e., breakpoints, for Neisseria meningitidis. PK parameters, protein binding, percentage penetration into cerebrospinal fluid (CSF), and the variability of these values, were extracted from the published literature for the 15 agents. PK-PD parameters have not been developed specifically for N. meningitidis in animal or human studies. Thus, it was necessary to invoke PK-PD targets from other organisms that cause infections at similar sites. The PK-PD targets utilised were: time above the MIC for at least 50% of the dosing interval for all beta-lactams, chloramphenicol, sulphafurazole and trimethoprim-sulphamethoxazole; an AUC/MIC ratio of >or=25 for the tetracyclines and macrolides; and an AUC/MIC ratio of >or=125 for the fluoroquinolones. A 10 000-subject Monte Carlo simulation was designed with the usual dosing regimens of each antimicrobial agent at MIC values of 0.03-64 mg/L in both serum and CSF. The PK-PD breakpoint was defined as the MIC at which the calculated target attainment was >or=95%. Using these assumptions, the proposed PK-PD breakpoints were: azithromycin, 0.125 mg/L; doxycycline, 0.25 mg/L; cefotaxime, ciprofloxacin and levofloxacin, 0.5 mg/L; penicillin G, meropenem, rifampicin, tetracycline and minocycline, 1 mg/L; chloramphenicol and sulphafurazole, 2 mg/L; and ampicillin, ceftriaxone and trimethoprim-sulphamethoxazole, 4 mg/L. Proposed PK-PD breakpoints applicable to CSF were: penicillin and cefotaxime, 0.06 mg/L; rifampicin, 0.125 mg/L; ceftriaxone, meropenem and trimethoprim-sulphamethoxazole, 0.25 mg/L; ampicillin, 0.5 mg/L; and chloramphenicol, 1 mg/L.
Assuntos
Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/farmacologia , Simulação por Computador , Infecções Meningocócicas/tratamento farmacológico , Método de Monte Carlo , Neisseria meningitidis/efeitos dos fármacos , Animais , Anti-Infecciosos/líquido cefalorraquidiano , Anti-Infecciosos/farmacocinética , Esquema de Medicação , Humanos , Testes de Sensibilidade MicrobianaRESUMO
Linezolid is a new antimicrobial agent effective against drug-resistant gram-positive pathogens commonly responsible for central nervous system (CNS) infections in neurosurgical patients hospitalized in intensive care units. In order to study the penetration of this antimicrobial into the cerebrospinal fluid (CSF) of such patients, the disposition of linezolid in serum and CSF was studied in 14 neurosurgical patients given linezolid at 600 mg twice daily (1-h intravenous infusion) for the treatment of CNS infections caused by gram-positive pathogens or for prophylactic chemotherapy. Serum and CSF linezolid steady-state concentrations were analyzed by high-pressure liquid chromatography, and the concentration-time profiles obtained were analyzed to estimate pharmacokinetic parameters. The mean +/- standard deviation (SD) linezolid maximum and minimum measured concentrations were 18.6 +/- 9.6 microg/ml and 5.6 +/- 5.0 microg/ml, respectively, in serum and 10.8 +/- 5.7 microg/ml and 6.1 +/- 4.2 microg/ml, respectively, in CSF. The mean +/- SD areas under the concentration-time curves (AUCs) were 128.7 +/- 83.9 microg x h/ml for serum and 101.6 +/- 59.6 microg x h/ml for CSF, with a mean penetration ratio for the AUC for CSF to the AUC for serum of 0.66. The mean elimination half-life of linezolid in CSF was longer than that in serum (19.1 +/- 19.0 h and 6.5 +/- 3.6 h, respectively). The serum and CSF linezolid concentrations exceeded the pharmacodynamic breakpoint of 4 microg/ml for susceptible target pathogens for the entire dosing interval in the majority of patients. These findings suggest that linezolid may achieve adequate concentrations in the CSF of patients requiring antibiotics for the management or prophylaxis of CNS infections caused by gram-positive pathogens.
Assuntos
Acetamidas/sangue , Acetamidas/líquido cefalorraquidiano , Anti-Infecciosos/sangue , Anti-Infecciosos/líquido cefalorraquidiano , Infecções Bacterianas/sangue , Encefalopatias/cirurgia , Oxazolidinonas/sangue , Oxazolidinonas/líquido cefalorraquidiano , Adulto , Idoso , Área Sob a Curva , Infecções Bacterianas/líquido cefalorraquidiano , Infecções Bacterianas/tratamento farmacológico , Encefalopatias/complicações , Cromatografia Líquida de Alta Pressão , Estado Terminal , Feminino , Bactérias Gram-Positivas/efeitos dos fármacos , Meia-Vida , Humanos , Linezolida , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Procedimentos Neurocirúrgicos , Estudos ProspectivosRESUMO
OBJECTIVE: To describe a case of coagulase-negative Staphylococcus ventriculitis successfully treated with oral linezolid, for which good cerebrospinal fluid (CSF) penetration was observed. CASE SUMMARY: A 69-year-old man had an extraventricular drain inserted following a right cerebellar infarct. On day 6, the CSF culture was positive for coagulase-negative staphylococci; intravenous vancomycin 1 g daily was initiated to treat ventriculitis. A ventriculoperitoneal shunt, inserted on day 35 to manage communicating hydrocephalus, was subsequently removed as symptoms suggesting infection presented. Coagulase-negative Staphylococcus was isolated from shunt reservoir aspirate, and intrathecal vancomycin 10 mg daily was added to the treatment regimen. On day 61, vancomycin was stopped and oral linezolid 600 mg twice daily was started. Linezolid was discontinued 22 days later, with no evidence of ongoing infection. Four blood samples were collected around the seventh dose of linezolid and 5 CSF samples were collected on separate days during treatment. Linezolid concentrations were measured in plasma and CSF by HPLC. Using an ADAPT II maximum a priori Bayesian estimator module, a 2 compartment pharmacokinetic model was fitted to the plasma linezolid concentration data and CSF:predicted plasma concentration ratios (ranging from 0.27 to 1.02) were derived. All CSF concentrations exceeded the reported 90% minimum inhibitory concentration of 2 mg/L for linezolid against coagulase-negative staphylococci. DISCUSSION: Evidence of the effectiveness of linezolid against central nervous system infections is growing; however, limited data exist describing its CSF penetration. Oral linezolid exhibited good CSF penetration in this patient, which corresponded to positive clinical response. CONCLUSIONS: Oral linezolid may play a valuable role in the treatment of multiresistant gram-positive central nervous system infections.
Assuntos
Acetamidas/uso terapêutico , Anti-Infecciosos/uso terapêutico , Ventrículos Cerebrais , Encefalite/tratamento farmacológico , Oxazolidinonas/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Acetamidas/sangue , Acetamidas/líquido cefalorraquidiano , Administração Oral , Idoso , Anti-Infecciosos/sangue , Anti-Infecciosos/líquido cefalorraquidiano , Encefalite/metabolismo , Encefalite/microbiologia , Humanos , Linezolida , Masculino , Oxazolidinonas/sangue , Oxazolidinonas/líquido cefalorraquidiano , Infecções Estafilocócicas/metabolismo , Infecções Estafilocócicas/microbiologiaRESUMO
The possible increase of ofloxacin levels in serum and cerebrospinal fluid (CSF) by concomitant indomethacin administration was investigated in 120 healthy adult rats. The animals were administered intramuscular doses of ofloxacin 30 mg/kg alone (Group A, n = 60) or with indomethacin 2 mg/kg (Group B, n = 60). Blood and CSF samples were obtained from both groups at 30, 45, 60 and 90 min post-administration. Concentrations of ofloxacin were estimated using a microbiological assay. Co-administration of indomethacin did not affect plasma levels of ofloxacin significantly; however, higher levels were found in all CSF samples after co-administration with indomethacin, particularly after 90 min with 0.59 microg/ml versus zero median values when only ofloxacin was administered (P = 0.05). No central nervous system adverse effects were observed clinically. No correlation between levels of ofloxacin in plasma and CSF could be established either in rats administered only ofloxacin or in rats administered both drugs. The presented pharmacokinetic findings revealed that co-administration of ofloxacin and indomethacin may result in protracted quinolone levels in the CSF. However, the absence of significant correlation between concentrations of ofloxacin in plasma and CSF upon co-administration of indomethacin, as well as of central nervous system adverse effects, make the probability of an epileptogenic interaction between them unlikely. These results merit further clinical evaluation.
Assuntos
Anti-Infecciosos/sangue , Anti-Infecciosos/líquido cefalorraquidiano , Anti-Inflamatórios não Esteroides/administração & dosagem , Indometacina/administração & dosagem , Ofloxacino/sangue , Ofloxacino/líquido cefalorraquidiano , Animais , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/efeitos adversos , Sistema Nervoso Central , Quimioterapia Combinada , Feminino , Ofloxacino/administração & dosagem , Ofloxacino/efeitos adversos , Ratos , Ratos WistarRESUMO
Cefotaxime, given in two doses (each 100 mg/kg of body weight), produced a good bactericidal activity (-0.47 Deltalog(10) CFU/ml. h) which was comparable to that of levofloxacin (-0.49 Deltalog(10) CFU/ml. h) against a penicillin-resistant pneumococcal strain WB4 in experimental meningitis. Cefotaxime combined with levofloxacin acted synergistically (-1.04 Deltalog(10) CFU/ml. h). Synergy between cefotaxime and levofloxacin was also demonstrated in vitro in time killing assays and with the checkerboard method for two penicillin-resistant strains (WB4 and KR4). Using in vitro cycling experiments, the addition of cefotaxime in sub-MIC concentrations (one-eighth of the MIC) drastically reduced levofloxacin-induced resistance in the same two strains (64-fold increase of the MIC of levofloxacin after 12 cycles versus 2-fold increase of the MIC of levofloxacin combined with cefotaxime). Mutations detected in the genes encoding topoisomerase IV (parC and parE) and gyrase (gyrA and gyrB) confirmed the levofloxacin-induced resistance in both strains. Addition of cefotaxime in low doses was able to suppress levofloxacin-induced resistance.
Assuntos
Anti-Infecciosos/uso terapêutico , Cefotaxima/uso terapêutico , Cefalosporinas/uso terapêutico , Levofloxacino , Meningite Pneumocócica/tratamento farmacológico , Ofloxacino/uso terapêutico , Streptococcus pneumoniae/efeitos dos fármacos , Streptococcus pneumoniae/genética , Animais , Anti-Infecciosos/líquido cefalorraquidiano , Anti-Infecciosos/farmacologia , Cefotaxima/líquido cefalorraquidiano , Cefotaxima/farmacologia , Cefalosporinas/líquido cefalorraquidiano , Cefalosporinas/farmacologia , DNA Bacteriano/genética , Farmacorresistência Bacteriana , Sinergismo Farmacológico , Meningite Pneumocócica/microbiologia , Testes de Sensibilidade Microbiana , Mutação/genética , Ofloxacino/líquido cefalorraquidiano , Ofloxacino/farmacologia , Resistência às Penicilinas , Coelhos , Reação em Cadeia da Polimerase Via Transcriptase ReversaRESUMO
The goals of the present study were to model the population kinetics of in vivo influx and efflux processes of grepafloxacin at the serum-cerebrospinal fluid (CSF) barrier and to propose a simulation-based approach to optimize the design of dose-finding trials in the meningitis rabbit model. Twenty-nine rabbits with pneumococcal meningitis receiving grepafloxacin at 15 mg/kg of body weight (intravenous administration at 0 h), 30 mg/kg (at 0 h), or 50 mg/kg twice (at 0 and 4 h) were studied. A three-compartment population pharmacokinetic model was fit to the data with the program NONMEM (Nonlinear Mixed Effects Modeling). Passive diffusion clearance (CL(diff)) and active efflux clearance (CL(active)) are transfer kinetic modeling parameters. Influx clearance is assumed to be equal to CL(diff), and efflux clearance is the sum of CL(diff), CL(active), and bulk flow clearance (CL(bulk)). The average influx clearance for the population was 0.0055 ml/min (interindividual variability, 17%). Passive diffusion clearance was greater in rabbits receiving grepafloxacin at 15 mg/kg than in those treated with higher doses (0.0088 versus 0.0034 ml/min). Assuming a CL(bulk) of 0.01 ml/min, CL(active) was estimated to be 0.017 ml/min (11%), and clearance by total efflux was estimated to be 0.032 ml/min. The population kinetic model allows not only to quantify in vivo efflux and influx mechanisms at the serum-CSF barrier but also to analyze the effects of different dose regimens on transfer kinetic parameters in the rabbit meningitis model. The modeling-based approach also provides a tool for the simulation and prediction of various outcomes in which researchers might be interested, which is of great potential in designing dose-finding trials.
Assuntos
Anti-Infecciosos/farmacocinética , Fluoroquinolonas , Meningite Pneumocócica/tratamento farmacológico , Piperazinas/farmacocinética , Animais , Anti-Infecciosos/sangue , Anti-Infecciosos/líquido cefalorraquidiano , Anti-Infecciosos/uso terapêutico , Área Sob a Curva , Meningite Pneumocócica/sangue , Meningite Pneumocócica/líquido cefalorraquidiano , Taxa de Depuração Metabólica , Modelos Biológicos , Piperazinas/sangue , Piperazinas/líquido cefalorraquidiano , Piperazinas/uso terapêutico , CoelhosRESUMO
T-3811ME (BMS-284756) is a new des-F(6)-quinolone with high levels of activity against gram-positive bacteria, including penicillin-resistant Streptococcus pneumoniae (PRSP) strains. T-3811, the free base of T-3811ME, exhibited potent activity against 28 clinical strains of PRSP isolated clinically (MIC at which 90% of the isolates tested are inhibited, 0.0625 microg/ml). After the intravenous dosing of T-3811ME (20 mg/kg of body weight as T-3811) in rabbits with meningitis caused by PRSP, the area under the concentration-time curve (AUC) of T-3811 in cerebrospinal fluid (CSF) was 5.79 microg. h/ml and was 4.5-fold higher than that of T-3811in the CSF of rabbits without meningitis. In addition, the AUC/MIC for T-3811ME (20 mg/kg as T-3811) in CSF was 185, which was 4.3-fold higher than that for ceftriaxone (administered intravenously at 100 mg/kg). After the administration of any dose of T-3811ME (5, 10, and 20 mg/kg as T-3811), the viable cell counts in CSF decreased in a dose-dependent manner. In particular, after dosing of 20 mg/kg (as T-3811), the viable cell counts in CSF were significantly less than those in the nontreated group (P < 0.01). By histopathological evaluation, 6 h after the administration of T-3811ME (20 mg/kg as T-3811), the thickening of the cerebral meninx and the infiltration of neutrophils into the cerebral meninx were less severe in the treated group than in the nontreated group. T-3811ME (BMS-284756) may be expected to be evaluated for the management of meningitis caused by highly penicillin-resistant pneumococci.
Assuntos
Anti-Infecciosos/uso terapêutico , Indóis/uso terapêutico , Meningite Pneumocócica/tratamento farmacológico , Quinolonas/uso terapêutico , Streptococcus pneumoniae/efeitos dos fármacos , Animais , Anti-Infecciosos/líquido cefalorraquidiano , Encéfalo/patologia , Ceftriaxona/uso terapêutico , Cefalosporinas/uso terapêutico , Fluoroquinolonas , Indóis/líquido cefalorraquidiano , Injeções Intravenosas , Isoindóis , Masculino , Meningite Pneumocócica/líquido cefalorraquidiano , Meningite Pneumocócica/microbiologia , Resistência às Penicilinas , Quinolonas/líquido cefalorraquidiano , CoelhosAssuntos
Acetamidas/líquido cefalorraquidiano , Anti-Infecciosos/líquido cefalorraquidiano , Antibioticoprofilaxia , Infecções do Sistema Nervoso Central/líquido cefalorraquidiano , Oxazolidinonas/líquido cefalorraquidiano , Complicações Pós-Operatórias/líquido cefalorraquidiano , Acetamidas/farmacocinética , Acetamidas/uso terapêutico , Anti-Infecciosos/farmacocinética , Anti-Infecciosos/uso terapêutico , Infecções do Sistema Nervoso Central/tratamento farmacológico , Humanos , Linezolida , Meningites Bacterianas/líquido cefalorraquidiano , Meningites Bacterianas/tratamento farmacológico , Oxazolidinonas/farmacocinética , Oxazolidinonas/uso terapêutico , Complicações Pós-Operatórias/microbiologiaRESUMO
BMS 284756 penetrated well into inflamed meninges (44% +/- 11%) and produced good bactericidal activity (-0.82 +/- 0.22 Delta log(10) CFU/ml. h) in the treatment of experimental meningitis in rabbits due to a penicillin-sensitive strain. BMS 284756 monotherapy had a greater potency than the standard regimen of ceftriaxone and vancomycin (-0.49 +/- 0.08 Delta log(10) CFU/ml. h) against a penicillin-resistant strain (MIC, 4 mg/liter). Even against a penicillin- and quinolone-resistant strain, BMS 284756 showed good bactericidal activity (-0.52 +/- 0.12 Delta log(10) CFU/ml. h). The antibacterial activity of BMS 284756 was confirmed by time-killing assays over 8 h in vitro.
Assuntos
Anti-Infecciosos/uso terapêutico , Fluoroquinolonas , Indóis , Meningite Pneumocócica/tratamento farmacológico , Quinolonas , Streptococcus pneumoniae/efeitos dos fármacos , 4-Quinolonas , Animais , Anti-Infecciosos/líquido cefalorraquidiano , Anti-Infecciosos/farmacologia , Modelos Animais de Doenças , Meningite Pneumocócica/líquido cefalorraquidiano , Meningite Pneumocócica/microbiologia , Testes de Sensibilidade Microbiana , Resistência às Penicilinas , Coelhos , Resultado do TratamentoRESUMO
Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Deltalog(10) CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were -5.70, -6.62, and -7.02; -7.37, -7.37, and -6.87; and -6.62, -6.62, and -6.62, respectively, whereas those of ceftriaxone and meropenem were -4.18, -5.24, and -4.43, and -3.64, -3.59, and -4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and C(max)/MBC were interrelated (r = 0.81); there was less correlation with T > MBC (r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF.
Assuntos
Anti-Infecciosos/farmacocinética , Anti-Infecciosos/uso terapêutico , Compostos Aza , Fluoroquinolonas , Meningite devida a Escherichia coli/tratamento farmacológico , Quinolinas , Animais , Anti-Infecciosos/líquido cefalorraquidiano , Área Sob a Curva , Ceftriaxona/uso terapêutico , Cefalosporinas/uso terapêutico , Escherichia coli/efeitos dos fármacos , Masculino , Meningite devida a Escherichia coli/líquido cefalorraquidiano , Meningite devida a Escherichia coli/microbiologia , Meropeném , Testes de Sensibilidade Microbiana , Moxifloxacina , Coelhos , Tienamicinas/uso terapêuticoRESUMO
BMS-284756 is a novel des-fluoro(6) quinolone with a broad antimicrobial activity, including Streptococcus pneumoniae. The purpose of this study was to evaluate the pharmacodynamic profile and effectiveness of BMS-284756 for therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant S. pneumoniae (CRSP). Meningitis was induced in rabbits by intracisternal inoculation of CRSP. BMS-284756 was given intravenously 16 h after intracisternal inoculation in single doses of 2.5 (n = 5 animals), 5 (n = 6), 10 (n = 6), 20 (n = 8), and 30 mg/kg (n = 6), in two doses of 10 mg/kg each separated by 5 h (n = 4), and as a 20-mg/kg dose followed 5 h later by 10 mg/kg (n = 5). The MICs and MBCs of BMS-284756, ceftriaxone, and vancomycin were 0.06 and 0.06, 4 and 4, and 0.25 and 0.25 microg/ml, respectively. After single doses of 10, 20, and 30 mg/kg, the maximum concentrations in cerebrospinal fluid (CSF) (mean +/- standard deviation) were 0.32 +/- 0.12, 0.81 +/- 0.38, and 1.08 +/- 0.43 microg/ml, respectively; the elimination half-life in CSF was 4.5 to 6.3 h. The CSF bacterial killing rates (BKR) at 5 h of the single-dose regimens of 10, 20 and 30 mg/kg were -0.84 +/- 0.48, -1.09 +/- 0.32, and -1.35 +/- 0.05 Deltalog(10) CFU/ml/h. The BKR(0-5) of the divided regimens (10 mg/kg twice and 20 mg/kg followed by 10 mg/kg) was -0.82 +/- 0.52 and -1.24 +/- 0.34 Deltalog(10) CFU/ml/h, respectively. The BKR(0-5) of the combined therapy with vancomycin and ceftriaxone was -1.09 +/- 0.39 Deltalog(10) CFU/ml/h. The penetration of BMS-284756 into purulent CSF relative to plasma was 14 to 25%. The bactericidal effect of BMS-284756 in CSF was concentration dependent. BMS-284756 at 30 mg/kg as a single or divided dose was as effective as standard therapy with vancomycin and ceftriaxone.
Assuntos
Anti-Infecciosos/uso terapêutico , Resistência às Cefalosporinas , Fluoroquinolonas , Indóis , Meningite Pneumocócica/tratamento farmacológico , Quinolonas , Animais , Antibacterianos/uso terapêutico , Anti-Infecciosos/líquido cefalorraquidiano , Anti-Infecciosos/farmacocinética , Ceftriaxona/farmacologia , Ceftriaxona/uso terapêutico , Masculino , Meningite Pneumocócica/líquido cefalorraquidiano , Meningite Pneumocócica/microbiologia , Testes de Sensibilidade Microbiana , Resistência às Penicilinas , Coelhos , Vancomicina/uso terapêuticoRESUMO
We have assessed levofloxacin penetration in cerebrospinal fluid (CSF) and the liquor-to-plasma ratio (C(L)/C(P)) at 2 hours after dosing in 5 patients with spontaneous acute bacterial meningitis. CSF levofloxacin concentration at 2 hours after dosing was 1.99+/-0.67 microg/mL, and the C(L)/C(P) at 2 hours after dosing was 0.34+/-0.09.
Assuntos
Anti-Infecciosos/líquido cefalorraquidiano , Levofloxacino , Meningite devida a Escherichia coli/líquido cefalorraquidiano , Meningite Meningocócica/líquido cefalorraquidiano , Meningite Pneumocócica/líquido cefalorraquidiano , Ofloxacino/líquido cefalorraquidiano , Doença Aguda , Adulto , Idoso , Anti-Infecciosos/farmacocinética , Anti-Infecciosos/uso terapêutico , Feminino , Humanos , Masculino , Meningite devida a Escherichia coli/tratamento farmacológico , Meningite Meningocócica/tratamento farmacológico , Meningite Pneumocócica/tratamento farmacológico , Pessoa de Meia-Idade , Ofloxacino/farmacocinética , Ofloxacino/uso terapêuticoRESUMO
This study was designed to investigate the penetration across the blood-brain barrier of three doses of levofloxacin using a microdialysis probe implanted into the cerebrospinal fluid (CSF) of a rabbit pneumococcal meningitis model. The microdialysis guide cannula was implanted into rabbit subarachnoid space using a stereotaxic frame. After 3 days, 10(4) cfu Streptococcus pneumoniae serotype 3 in 0.3 mL saline was injected via intracisternal puncture and animals were allowed to incubate the organisms for 16-18 h. Groups of animals (n = 5) then received 7, 10.5 or 14 mg/kg iv of the drug over 10 min. Plasma samples were obtained via an ear vein 0, 0.25, 0.5, 0.75, 1, 2, 4, 6 and 8 h after the antibiotic infusion. CSF microdialysis effluent samples were collected every 0.5 h for the entire experiment. Plasma and microdialysis effluent samples were analysed by HPLC. AUC(0-8) in plasma and CSF were computed using the trapezoid rule. The elimination half-life in plasma and CSF was calculated using non-linear regression analysis. The unbound peak plasma concentrations for the three doses studied were 3.9, 6.4 and 10.3 mg/L, respectively. There was a significant increase in the plasma AUC(0-8) [29.7 +/- 6.3, 49.1 +/- 19.1 and 67.6 +/- 8.9 mg x h/L (P < 0.005)]. The unbound peak CSF concentrations were 3.8, 5.7 and 8.6 mg/L and occurred at 0-0.5 h after the administration of the dose. The AUC(CSF(0-8)) was significantly higher as the dose was increased (7 mg/kg, 15.8 +/- 6.6; 10.5 mg/kg, 37.3 +/- 7.8; and 14 mg/kg, 46.4 +/- 20.9 mg x h/L; P < 0.03). The penetration of levofloxacin averaged 53% for the 7 mg/kg dosage group, 76% for the 10.5 mg/kg group and 68% for the 14 mg/kg group. Our results demonstrate that levofloxacin penetration into the CSF averages 66% for the doses that would be used in clinical practice.
Assuntos
Anti-Infecciosos/líquido cefalorraquidiano , Levofloxacino , Meningite Pneumocócica/líquido cefalorraquidiano , Ofloxacino/líquido cefalorraquidiano , Animais , Anti-Infecciosos/farmacocinética , Área Sob a Curva , Modelos Animais de Doenças , Meningite Pneumocócica/metabolismo , Ofloxacino/farmacocinética , Coelhos , Streptococcus pneumoniae/efeitos dos fármacosRESUMO
Gatifloxacin penetrated well into cerebrospinal fluid (CSF) (49 +/- 11%), measured by comparison of AUC(CSF)/AUC(serum), and showed good bactericidal activity (leading to a decrease of 0.75 +/- 0.17 log10 cfu/mL/h) in the treatment of experimental meningitis in rabbits caused by a penicillin-resistant pneumococcal strain (MIC 4 mg/L). It was significantly more effective than the standard regimen, ceftriaxone with vancomycin, which led to a decrease of 0.53 +/- 0.17 log10 cfu/mL/h. The addition of cefepime to gatifloxacin slightly improved the killing rates (giving a decrease of 0.84 +/- 0.14 log10 cfu/mL/h). In vitro, synergy was demonstrated between cefepime and gatifloxacin by the chequerboard method (fractional inhibitory concentration index = 0.5) and by viable counts over 8 h.
Assuntos
Anti-Infecciosos/uso terapêutico , Cefalosporinas/uso terapêutico , Fluoroquinolonas , Meningites Bacterianas/tratamento farmacológico , Animais , Anti-Infecciosos/líquido cefalorraquidiano , Cefepima , Cefalosporinas/líquido cefalorraquidiano , Modelos Animais de Doenças , Quimioterapia Combinada , Gatifloxacina , Meningites Bacterianas/metabolismo , Testes de Sensibilidade Microbiana , Resistência às Penicilinas , Coelhos , Streptococcus pneumoniae/efeitos dos fármacos , Resultado do TratamentoRESUMO
Nosocomial meningitis due to gram-negative organisms is a difficult clinical problem to manage because of both antibiotic resistance and poor penetration of many antimicrobials across the blood-brain barrier. Ciprofloxacin has potential in treating this condition when used in high doses. We investigated the plasma and cerebrospinal fluid (CSF) levels of ciprofloxacin in a patient with Pseudomonas aeruginosa meningitis who was treated with 400 mg of intravenous ciprofloxacin every 8 hours. Ciprofloxacin levels in plasma peaked at 10.29 mg/L without resulting in accumulation (8-hour trough levels, <1 mg/L), whereas the CSF level increased to 0.9 mg/L. This CSF level was confirmed to be similar 1 week later. After 1 week of therapy, during which there were no side effects attributable to ciprofloxacin, the organism was eradicated, and there was some clinical improvement. We recommend that 400 mg of intravenous ciprofloxacin every 8 hours be considered for treatment of difficult-to-treat gram-negative bacillary meningitis.